The iconic status of Viagra, and the parent firm copyright, presents a challenging question for shareholders . While revenues initially exploded , the looming patent expiry and growing generic presence https://brianlcpt073073.blogstival.com/63133944/the-blue-pill-and-the-pharmaceutical-industry-a-risky-investment